Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
Authors
Keywords
-
Journal
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
Volume Volume 13, Issue -, Pages 2781-2799
Publisher
Informa UK Limited
Online
2020-08-05
DOI
10.2147/dmso.s258593
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circadian rhythm disruption and mental health
- (2020) William H. Walker et al. Translational Psychiatry
- Chronic Sympathetic Hyperactivity Triggers Electrophysiological Remodeling and Disrupts Excitation-Contraction Coupling in Heart
- (2020) Humberto C. Joca et al. Scientific Reports
- Investigating the Effects of Brainstem Neuronal Adaptation on Cardiovascular Homeostasis
- (2020) James H. Park et al. Frontiers in Neuroscience
- Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications
- (2020) Min Gong et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF
- (2020) Pooja Dewan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Potential Deep Brain Stimulation Targets for the Management of Refractory Hypertension
- (2019) Raleigh Ems et al. Frontiers in Neuroscience
- Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome
- (2019) Christian Templin et al. EUROPEAN HEART JOURNAL
- Sex differences in brain activation patterns with mental stress in patients with coronary artery disease
- (2019) Nicole Kasher et al. Biology of Sex Differences
- Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
- (2019) Robert J. Chilton DIABETES OBESITY & METABOLISM
- Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options
- (2019) Edoardo Gronda et al. HEART FAILURE REVIEWS
- The central autonomic network at rest: Uncovering functional MRI correlates of time-varying autonomic outflow
- (2019) G. Valenza et al. NEUROIMAGE
- The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
- (2019) Dhiren K. Patel et al. Diabetes Therapy
- CVOTs: What did the endocrinologist learn?
- (2019) Paul Valensi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
- (2018) Mumin Alper Erdogan et al. BMC Neurology
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- (2018) Motoaki Sano Journal of Cardiology
- Brain Correlates of Mental Stress-Induced Myocardial Ischemia
- (2018) J. Douglas Bremner et al. PSYCHOSOMATIC MEDICINE
- Central Mechanisms for Thermoregulation
- (2018) S.F. Morrison et al. Annual Review of Physiology
- An overview of energy and metabolic regulation
- (2018) Song Wen et al. Science China-Life Sciences
- Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
- (2017) Farhana Naznin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
- (2017) Vance B. Matthews et al. JOURNAL OF HYPERTENSION
- The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
- (2017) Jens Jordan et al. Journal of the American Society of Hypertension
- SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
- (2017) Piangkwan Sa-nguanmoo et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Glucose-Sensing in the Reward System
- (2017) Laura L. Koekkoek et al. Frontiers in Neuroscience
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Major Autonomic Neuroregulatory Pathways Underlying Short- and Long-Term Control of Cardiovascular Function
- (2016) Ibrahim M. Salman CURRENT HYPERTENSION REPORTS
- Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
- (2016) A.J. Scheen DIABETES & METABOLISM
- Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
- (2016) Leszek Szablewski JOURNAL OF ALZHEIMERS DISEASE
- Is it time to think about the sodium glucose co-transporter 2 sympathetically?
- (2016) Rosemary H Elliott et al. NEPHROLOGY
- Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
- (2016) Yumiko Chiba et al. PLoS One
- The median preoptic nucleus: front and centre for the regulation of body fluid, sodium, temperature, sleep and cardiovascular homeostasis
- (2015) M. J. McKinley et al. Acta Physiologica
- Role of neurons and glia in the CNS actions of the renin-angiotensin system in cardiovascular control
- (2015) Annette D. de Kloet et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Transport of Sugars
- (2015) Li-Qing Chen et al. Annual Review of Biochemistry
- Forebrain organization for autonomic cardiovascular control
- (2015) J. Kevin Shoemaker et al. AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
- Hypothalamic Signaling Mechanisms in Hypertension
- (2015) Casey Y. Carmichael et al. CURRENT HYPERTENSION REPORTS
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
- (2012) Ivan Sabolić et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Regional distribution of SGLT activity in rat brain in vivo
- (2012) Amy S. Yu et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- The Medial Amygdalar Nucleus: A Novel Glucose-Sensing Region That Modulates the Counterregulatory Response to Hypoglycemia
- (2010) L. Zhou et al. DIABETES
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Transgenic Mice Expressing Green Fluorescent Protein under the Control of the Corticotropin-Releasing Hormone Promoter
- (2009) Tamar Alon et al. ENDOCRINOLOGY
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Measurement of Immediate-Early Gene Activation-c-fosand Beyond
- (2008) K. J. Kovács JOURNAL OF NEUROENDOCRINOLOGY
- A Functional Role for Sodium-Dependent Glucose Transport across the Blood-Brain Barrier during Oxygen Glucose Deprivation
- (2008) S. Vemula et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search